This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 27/7/1500    most recent ATVBAHA.107.144220v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Finn, A. V. Articles by Virmani, R. Search for Related Content PubMed PubMed Citation Articles by Finn, A. V. Articles by Virmani, R. Related Collections Catheter-based coronary interventions: stents

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:1500.)
© 2007 American Heart Association, Inc.

Brief Reviews

Vascular Responses to Drug Eluting Stents

Importance of Delayed Healing

Aloke V. Finn; Gaku Nakazawa; Michael Joner; Frank D. Kolodgie; Erik K. Mont; Herman K. Gold; Renu Virmani

From CVPath Institute, Inc (G.N., M.J., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston; and Miami Dade County Medial Examiner Department (E.K.M.), Miami, Fla.

Correspondence to Renu Virmani, MD, Medical Director, CVPath Institute, Inc, 19 Firstfield, Road, Gaithersburg, MD 20878. E-mail rvirmani{at}cvpath.org

Polymer-based sirolimus- (Cypher) and paclitaxel-eluting (Taxus) drug eluting stents have become the treatment of choice for patients with symptomatic coronary artery disease undergoing percutaneous coronary intervention (PCI). Although these stents reduce rates of restenosis compared with bare metal stents (BMS), late thrombosis, a life threatening complication, has emerged as a major safety concern. Our understanding of the pathophysiology of late DES thrombosis is derived from animal and human pathologic samples taken after implantation of these devices. These data indicate that both DES cause substantial impairment in arterial healing characterized by lack of complete reendothelialization and persistence of fibrin when compared with BMS. This delayed healing is the primary substrate underlying all cases of late DES thrombosis at autopsy. Several additional risk factors for late stent thrombosis such as penetration of necrotic core, malapposition, overlapping stent placement, excessive stent length, and bifurcation lesions represent additional barriers to healing and should be avoided if DES are to be used to minimize the risk of late thrombosis. Because the time course of complete healing with DES in man is unknown, the optimal duration of antiplatelet treatment remains to be determined.

Late thrombosis after polymer-based sirolimus- (Cypher) and paclitaxel-eluting (Taxus) drug eluting stents has emerged as a major safety concern. This review will summarize our current understanding of the vascular response to these DES in both humans and animals, especially as it pertains to the issue of late DES thrombosis.

Key Words: stents • thrombosis • endothelium

This article has been cited by other articles:

				M. I. Hamilos, M. Ostojic, B. Beleslin, D. Sagic, L. Mangovski, S. Stojkovic, M. Nedeljkovic, D. Orlic, B. Milosavljevic, D. Topic, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2123 - 2129. [Abstract] [Full Text] [PDF]

				S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era? Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 137 - 146. [Abstract] [PDF]

				R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]

				M. W. Krucoff, D. J. Kereiakes, J. L. Petersen, R. Mehran, V. Hasselblad, A. J. Lansky, P. J. Fitzgerald, J. Garg, M. A. Turco, C. A. Simonton III, et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1543 - 1552. [Abstract] [Full Text] [PDF]

				G. Nakazawa, Q. Cheng, X. Xu, A. V. Finn, F. D. Kolodgie, and R. Virmani Drug-eluting stent implantation may not affect vasomotor function in early phase. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1124 - 1125. [Full Text] [PDF]

				J. Aoki, A. Kirtane, M. B. Leon, and G. Dangas Coronary Artery Aneurysms After Drug-Eluting Stent Implantation J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 14 - 21. [Abstract] [Full Text] [PDF]

				R. Jabara, N. Chronos, D. Conway, W. Molema, and K. Robinson Evaluation of a Novel Slow-Release Paclitaxel-Eluting Stent With a Bioabsorbable Polymeric Surface Coating J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 81 - 87. [Abstract] [Full Text] [PDF]